Growth Metrics

Innoviva (INVA) Current Deferred Revenue (2016 - 2026)

Innoviva filings provide 12 years of Current Deferred Revenue readings, the most recent being $4.3 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 279.22% to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 million, a 279.22% increase, with the full-year FY2025 number at $4.3 million, up 279.22% from a year prior.
  • Current Deferred Revenue hit $4.3 million in Q4 2025 for Innoviva, down from $13.6 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $13.6 million in Q3 2025 to a low of $717000.0 in Q3 2024.
  • Median Current Deferred Revenue over the past 4 years was $1.8 million (2022), compared with a mean of $2.8 million.
  • Biggest five-year swings in Current Deferred Revenue: crashed 73.72% in 2024 and later surged 1792.75% in 2025.
  • Innoviva's Current Deferred Revenue stood at $2.1 million in 2022, then crashed by 39.02% to $1.3 million in 2023, then dropped by 11.82% to $1.1 million in 2024, then skyrocketed by 279.22% to $4.3 million in 2025.
  • The last three reported values for Current Deferred Revenue were $4.3 million (Q4 2025), $13.6 million (Q3 2025), and $3.1 million (Q2 2025) per Business Quant data.